Chemours price target lowered to $25 from $27 at Credit Suisse

Credit Suisse analyst John Roberts lowered the firm’s price target on Chemours to $25 from $27 and keeps an Underperform rating on the shares following the Q1 results. The firm sees a slower improvement in margins, particularly in the Titanium Technologies segment than previously anticipated, the analyst tells investors in a research note.